Patient Financial Counselor

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal. * Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment-refractory solid tumors * Decentralized point-of-care manufacturing of APN401 was feasible across manufacturing sites * APN401 demonstrated a favorable safety profile, with no dose-limiting toxicities or grade >=3 treatment-related adverse events * Disease stabilization was observed in 5 of 10 RECIST-evaluable patients Vienna, Austria, Oct. 15, 2026 (GLOBE NEWSWIRE) - invIOs GmbH ("invIOs"), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology. The publication, "Phase I Evaluation of APN401, an Autologous CBL-B-Silenced PBMC Therapy, in Advanced Solid Tumors", reports findings from two Phase 1 studies evaluating APN401 in patients with advanced, treatment-refractory solid tumors. A total of 17 patients received APN401 across three dose levels. The patients had advanced solid tumors and had received between two and eleven prior lines of systemic therapy. The treatment was well tolerated, with no dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or grade >=3 treatment-related adverse events. The highest dose of 4.5 x 10[7] PBMCs/kg was selected as the recommended Phase 2 dose. Disease stabilization was observed in 5 out of 10 RECIST-evaluable patients. Exploratory immune profiling identified systemic changes following APN401 treatment, including increased levels of cytotoxic mediators and expansion of specific T-cell populations. These changes were most pronounced in patients with stable disease. This suggests that APN401 can enhance immune activity against the tumor and that this effect may be linked to clinical benefit. APN401 is an autologous cell therapy utilizing patients' own PBMCs in which the intracellular immune checkpoint CBL-B is transiently silenced using siRNA. CBL-B acts as a brake on the immune system: it negatively regulates antigen receptor signaling and T-cell activation. By temporarily reducing CBL-B activity in immune cells, APN401 cell therapy is engineered to overcome the immunosuppressive tumor microenvironment and attack tumor cells. Romana Gugenberger, PhD, Managing Director of invIOs, commented: "We are thrilled to see our clinical data with APN401 published in a peer-reviewed journal. We are encouraged by the favorable safety profile, the disease stabilization observed, and the systemic immune changes following treatment. This is especially noteworthy considering that these patients had already received multiple prior lines of therapy. These results highlight the promise of CBL-B silencing as a new approach in immuno-oncology and demonstrate that our EPiC cell manufacturing platform can reliably produce cell therapies through a rapid, decentralized manufacturing process. Together, these findings support further clinical evaluation of APN401 and our EPiC platform as we work towards new treatment options for patients with difficult-to-treat solid tumors." APN401 is produced using invIOs' proprietary EPiC(R) point-of-care platform, which allows for manufacturing of the cell therapy product with a vein-to-vein time of less than 24 hours. The study demonstrated reproducible manufacturing across sites and supported the feasibility of repeated administration. About invIOs invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of novel cancer therapies. The invIOs team applies its extensive knowledge of immune system activation to create personalized and targeted therapies for solid tumors. The company is progressing a pipeline of four programs that include both cell therapy and small molecule strategies. invIOs is also partnered with leading institutions and universities, including the Dana-Farber Cancer Institute, to co-develop treatments for glioblastoma. EPiC, invIOs' proprietary cell therapy platform, allows the creation of personalized cell therapies based on localized processing of a patient's fresh immune cells, enabling rapid treatment in an out-patient setting. The platform's lead asset, APN401, has successfully completed Phase 1 clinical trials in patients with various solid tumors. A second candidate, INV441, is currently being developed for glioblastoma and a first-in-human Phase 1 clinical trial is in planning. Additionally, INV451, the third EPiC-based program, represents a next-generation CAR-T cell approach targeting rare tumor types. INV501 is a novel orally available small molecule candidate that can selectively enhance anti-tumor immune responses. It induces T-cell activation, proliferation, and tumor-specific cytotoxicity. INV501 has demonstrated favorable bioavailability and preclinical proof of concept with strong data in multiple solid tumor indications. For further information, please visit www.invios.com and connect with us on LinkedIn.Vienna, Austria, Oct. 15, 2026 (GLOBE NEWSWIRE) - | invIOs Romana Gugenberger, PhD Managing Director T +43 1 8656577 0 Email: [email protected] | MC Services AG Dr. Cora Kaiser, Dr. Regina Lutz T +49 89 210 228 0 US: Laurie Doyle T +1-339-832-0752 Email: [email protected] | Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Joyce Liu wins prestigious award from the National Cancer Institute. Posted date October 9, 2026 Joyce Liu, MD, MPH of Dana-Farber Cancer Institute is the recipient of the 2026 Michaele C. Christian Oncology Drug Development Award and Lectureship from the National Cancer Institute (NCI). The prestigious honor awarded annually recognizes individuals who have made significant contributions to the development of novel investigational agents for cancer therapy. Liu serves as associate chief and clinical research director of the Division of Gynecologic Oncology at Dana-Farber. In these roles, Liu has successfully developed and led multiple investigator-initiated and industry-sponsored phase 1 and 2 trials in GYN cancers, including early development of antibody-drug conjugates and combinations of PARP inhibitors with immuno-oncology agents. Her work has helped to establish the Dana-Farber GYN research program as a leading center for phase 1 and 2 trial development. Liu also serves as the associate clinical research officer for Dana-Farber. In presenting the award today, the National Cancer Institute stated, "Through her innovative clinical and translational research, Dr. Liu has advanced novel therapeutic strategies for ovarian and endometrial cancers, led practice-changing National Cancer Institute-sponsored clinical trials and championed the development of targeted therapies that have improved treatment options for patients worldwide." Liu's research focuses on identifying and validating novel therapies for gynecologic cancers, with an emphasis on rationally-designed, translationally-driven trials. Early in her career, she identified ErbB3 as a potential therapeutic target in ovarian cancer, leading to an international phase 2 trial of an ErbB3-directed antibody in conjunction with paclitaxel chemotherapy in recurrent platinum-resistant ovarian cancer. Dr. Liu also led the NCI-sponsored trial CTEP 8348 of combination cediranib and olaparib, which was the first trial to demonstrate the activity of combined anti-angiogenic and PARP inhibitor therapy in recurrent ovarian cancer. These results led to the NCI-sponsored international phase 3 NRG-GY004 trial comparing this combination to conventional chemotherapy in recurrent platinum-sensitive ovarian cancer, as well as CTEP 9825, a biomarker-driven phase 2 trial exploring potential biomarkers of sensitivity to this combination. Throughout her career, Liu has been an active member and leader within the NCI clinical trials network. Based upon work showing pre-clinical synergy between MEK inhibition and Bcl-xL inhibition in models of recurrent ovarian cancer, Liu developed and led CTEP 10597, a phase 1 trial testing the combination of cobimetinib with the Bcl-xL inhibitor pelcitoclax in recurrent ovarian and endometrial cancers, and she was an active contributor to CTEP 9525, a phase 1/2 study testing the combination of trametinib and navitoclax across solid tumors. Liu is also the current vice chair for the Ovarian Subcommittee of the NCI-funded NRG Oncology cooperative group. Liu is an active clinical trialist and is a principal investigator on multiple investigator-initiated and externally-sponsored interventional clinical studies in ovarian and endometrial cancer. She led the first trial demonstrating the clinical activity of WEE1 inhibition in uterine serous cancer and is a multi-PI of a P01 grant stemming from this work that is focused on understanding the role of replication stress in high-grade endometrial cancers. She also leads the Dana-Farber Gynecologic Oncology Division's translational modeling efforts and has developed panels of patient-derived xenograft and organoid models of ovarian and endometrial cancers that have provided insights into multiple novel therapeutic targets. Liu joins Panos Konstantinopoulos, MD, PhD (2022) and Geoff Shapiro, MD, PhD (2013) as Dana-Farber recipients of the Michaele C. Christian Oncology Drug Development Award. Gynecologic Cancer Related Doctors and Researchers Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us. Joyce F. Liu, MD, MPH

Seth Karp, MD, and Gavin Dunn MD, PhD, join Dana-Farber Cancer Institute. Posted date October 9, 2026 This week, two distinguished leaders joined Dana-Farber Cancer Institute: Seth Karp, MD, began his new role as Chair of Surgery, and Gavin P. Dunn, MD, PhD, is now Neurosurgeon-in-Chief at the Institute. Dr. Karp also serves as Chair of the Roberta and Stephen R. Weiner Department of Surgery at Beth Israel Deaconess Medical Center (BIDMC), and will play a central role in the Dana-Farber Beth Israel Deaconess Cancer Collaboration, which will bring together world-class clinicians to deliver transformational, precision medicine in an environment solely dedicated to defying cancer. Dr. Dunn is the inaugural Chair of a new Department of Neurosurgery at Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians. As Neurosurgeon-in-Chief, he will work with clinical leaders at Dana-Farber on the coordination and delivery of neurosurgical services as part of multidisciplinary oncology care as part of Dana-Farber's clinical collaboration with BIDMC. "I am thrilled to welcome Seth Karp and Gavin Dunn, two highly respected leaders and researchers, to Dana-Farber," said Benjamin L. Ebert, MD, PhD, president and CEO of Dana-Farber Cancer Institute. "Through our clinical collaboration with BIDMC, they will foster effective multidisciplinary care for patients and their families through world-class clinical services and innovation." Previously, Dr. Karp served as Chair of the Section of Surgical Sciences and System Surgeon-in-Chief at Vanderbilt University Medical Center. He was the H. William Scott Jr. Chair in Surgery and Professor of Surgery, Biomedical Ethics and Society, and Anesthesiology at Vanderbilt University School of Medicine. He joined the Vanderbilt faculty as Director of the Vanderbilt Transplant Center in 2011, and over the next 15 years, the Center became the largest in the United States. Dr. Karp is nationally known for his expertise in liver transplantation including the use of marginal grafts, and organ procurement and allocation. He has provided congressional testimony three times regarding national transplant policy. Dr. Karp has held numerous leadership positions in the American Society of Transplant Surgeons and the Organ Procurement and Transplantation Network and United Network for Organ Sharing (UNOS). He is former deputy editor of the American Journal of Transplantation, and a fellow of the American Surgical Association, American College of Surgeons, and Southern Surgical Association. Dr. Karp's clinical research interests include increasing the number of organs available for transplantation, improving organ procurement organization performance, and understanding and improving health for rural and underserved populations. His basic research examines the mechanisms of liver regeneration and treatment of monogenetic liver disease in children. Dr. Karp received his undergraduate degree in physics and astrophysics and his master's degree in astrophysics from Harvard University, and his medical degree from the joint Harvard/MIT program in health sciences and technology. He completed his residency at Brigham and Women's Hospital and transplant fellowship at The Johns Hopkins Hospital. Prior to joining Dana-Farber, Dr. Dunn served as Director of the Brain Tumor Immunology and Immunotherapy Program at Massachusetts General Hospital, where his clinical practice focused on caring for patients with primary and metastatic brain cancers, as well as general neurosurgical conditions. He is also a Professor of Neurosurgery at Harvard Medical School and a Captain in the United States Navy Reserves Medical Corps. Dr. Dunn is a Fellow and Member of the American Association of Neurological Surgeons, and a Member of the Congress of Neurological Surgeons and Society for Immunotherapy of Cancer. He also has served on the Board of Directors of the Society for Neuro-Oncology. Dr. Dunn's NIH-funded research focuses on understanding the immune response to brain tumors and the fundamental basis of CNS immunobiology. His work on the Brain Tumor Immunity cycle involves preclinical models and translational work that has resulted in the development of novel personalized cancer vaccine clinical studies. He is a co-chair of a clinical trial through the Alliance for Clinical Trials in Neuro-Oncology focused on recurrent glioblastoma. Dr. Dunn earned his undergraduate degree in molecular biology from Princeton University and his medical degree and PhD in immunology from Washington University in St. Louis. He completed his neurosurgery residency training at Massachusetts General Hospital and was a postdoctoral fellow with Executive Vice President & Chief Operating and Transformation Officer William C. Hahn, MD, PhD, at the Broad Institute and Dana-Farber Cancer Institute. Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us. Seth Karp, MD, Chair of Surgery Gavin P. Dunn, MD, PhD, Neurosurgeon-in-Chief